[go: up one dir, main page]

Stolfi et al., 1996 - Google Patents

Enhanced antitumor activity of an adriamycin+ 5-fluorouracil combination when preceded by biochemical modulation

Stolfi et al., 1996

Document ID
7492587549021989453
Author
Stolfi R
Colofiore J
Nord L
Martin D
Publication year
Publication venue
Anti-cancer drugs

External Links

Snippet

A three-drug combination, PMA, consisting of (phos-phonacetyl)-L-aspartic acid+ 6- methylmercaptopurine riboside+ 5-aminonlcotinamide, preceding either 5-fluorouraell (5- FU) or adriamycin (Adr), produced tumorregressing activity in a murine advanced breast …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles

Similar Documents

Publication Publication Date Title
US7381713B2 (en) Treatment of cancer by reduction of intracellular energy and pyrimidines
Grant et al. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA
Martin et al. ATP depletion+ pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach
Galmarini et al. Nucleoside analogues: mechanisms of drug resistance and reversal strategies
Epstein Drug-induced DNA damage and tumor chemosensitivity.
Binaschi et al. Mechanism of action of DNA topoisomerase inhibitors
Ben-Hur Involvement of poly (ADP-ribose) in the radiation response of mammalian cells
KREMER Drugs five years later: cytarabine
Ng et al. Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines
Niitsu et al. Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity
Boorstein et al. β-Lapachone greatly enhances MMS lethality to human fibroblasts
Gourdeau et al. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity
Tihan et al. Studies on the mechanisms of inhibition of L1210 cell growth by 3, 4-dihydroxybenzohydroxamic acid and 3, 4-dihydroxybenzamidoxime
Stolfi et al. Enhanced antitumor activity of an adriamycin+ 5-fluorouracil combination when preceded by biochemical modulation
Martin et al. Biochemical modulation of tumor cell energy in vivo: II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed
Wadler et al. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1, 2-bis (3, 5-dioxopiperazinyl-1-yl) propane (ICRF 187) against the murine sarcoma S180 cell line
Veale et al. Phase 1 study of high-dose hydroxyurea in lung cancer
Parsons et al. Properties of human melanoma cells resistant to 5-(3′, 3′-dimethyl-1-triazeno) imidazole-4-carboxamide and other methylating agents
Bachmann et al. Effects of Mitoxantrone and Doxorubicin on Energy Metabolism of the Rat Heart¹
Drewinko et al. The lethal activity of platinum compounds in combination with pyrimidine derivatives
Naoe et al. Cytotoxic mechanisms of FK317, a new class of bioreductive agent with potent antitumor activity
Kensler et al. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma
Cartee et al. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells
Colofiore et al. Biochemical modulation of tumor cell energy IV: evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression
Rawling et al. The effect of niacin deficiency on diethylnitrosamine‐induced hepatic poly (ADP‐ribose) levels and altered hepatic foci in the fischer‐344 rat